Abbreviated IDE Requirements for Nonsignificant Risk Studies with a Foreign Manufacturer

The rule foreign manufacturers must understand before starting a US clinical study

Under 21 CFR 812.18(a), a company outside the United States cannot itself sponsor an FDA investigational device exemption study. A US person or entity must act as the sponsor of record, even when the study qualifies for the abbreviated nonsignificant risk pathway. This is not a technicality that experienced regulatory professionals work around. It is a firm structural requirement of the IDE regulations, and it applies regardless of whether the foreign manufacturer has a US distributor, a US agent, or an existing 510(k) clearance.

Many regulatory affairs teams at non US device companies discover this requirement late in their clinical planning cycle, often after they have already designed the protocol and identified US investigational sites. Understanding the sponsor of record obligation early saves significant time and avoids the kind of procedural delays that compress study timelines and strain investor confidence.

What abbreviated requirements actually reduce and what they do not

The abbreviated IDE requirements under 21 CFR 812.2(b) reduce the paperwork burden for nonsignificant risk device studies. They do not reduce, waive, or modify the requirement for a US sponsor of record. A non US manufacturer conducting an abbreviated nonsignificant risk study in the United States still needs a qualified US sponsor to assume all sponsor obligations under 21 CFR Part 812.

Per 21 CFR 812.2(b), a sponsor of a device that poses a nonsignificant risk must, among other things, obtain IRB approval before initiating the study, maintain records, submit required reports to FDA, and label the device in accordance with 21 CFR 812.5. The full list of abbreviated requirements is available at the eCFR: 21 CFR 812.2(b) on eCFR. The point is straightforward: abbreviated means fewer submissions to FDA and a reduced administrative footprint. It does not mean the study operates without a sponsor. It does not mean a non US entity can step into that role.

Why the US sponsor requirement applies equally to nonsignificant risk studies

Some regulatory teams mistakenly assume that because an abbreviated nonsignificant risk study does not require IDE approval from FDA before it begins, the structural requirements of the IDE regulations are somehow lighter or more flexible. They are not. FDA's jurisdiction in these studies is exercised through the sponsor of record, who is responsible for interactions with IRBs, recordkeeping, adverse device effect reporting, and monitoring. If that sponsor is not a US person or entity, FDA has no clear domestic point of accountability.

21 CFR 812.18(a) addresses this directly by requiring that a foreign sponsor designate a US agent who will be the sponsor, not merely a contact. This is a meaningful distinction. The US sponsor of record accepts legal and regulatory responsibility for the study under US law. A foreign manufacturer can prepare its study materials, draft its protocols, and coordinate its clinical team, but the sponsor of record role must belong to a qualified US entity.

This applies the same way whether the study is a full IDE requiring FDA approval or an abbreviated study under the nonsignificant risk pathway. The pathway determines the submission requirements. It does not determine who must hold the sponsor role.

How to assess your study and assign the right sponsor of record

Before a non US manufacturer initiates any investigational study in the United States, the regulatory team should review three things: whether the device meets the nonsignificant risk criteria under 21 CFR 812.3(m), whether a qualified US entity is prepared to accept sponsor of record obligations, and whether that entity has the infrastructure to fulfill those obligations throughout the study duration.

ADB Consulting and CRO Inc. helps foreign manufacturers assess their IDE pathway, review their study designs for regulatory readiness, and prepare the documentation needed to support a compliant US sponsor of record designation. Visit adbccro.com/us-sponsor to review what the US sponsor role requires, use the US Sponsor Obligations Checklist to assess your current readiness, and use the US Sponsor Decision Tool to identify the right structure for your specific study.

ADB Consulting and CRO Inc. serves as US Sponsor of Record for foreign manufacturers conducting FDA regulated clinical investigations in the United States.

Reviewed November 3, 2026 by ADB's regulatory team.

Frequently asked questions

Can a non US manufacturer rely on its US distributor to serve as sponsor of record for an abbreviated nonsignificant risk study?

A US distributor can serve as sponsor of record if it is willing to accept all obligations under 21 CFR Part 812, including IRB coordination, adverse event reporting, and recordkeeping. However, most distributors are not structured to take on that regulatory exposure and do not have the internal processes to fulfill those duties. A qualified regulatory consulting firm or contract research organization with established sponsor of record infrastructure is typically a more appropriate choice. The critical requirement is that the US entity formally accepts the sponsor role, not merely agrees to be listed as a contact.

Does the nonsignificant risk determination eliminate the need to notify FDA before starting the study?

A nonsignificant risk determination made by the IRB, in accordance with FDA guidance, allows the study to proceed without prior FDA approval. However, the sponsor is still required to maintain records and submit certain reports to FDA during the course of the study. The abbreviated requirements under 21 CFR 812.2(b) reduce the pre-study submission burden, but they do not create a study that operates entirely outside FDA oversight. A US sponsor of record remains responsible for all required interactions with FDA throughout the study.

What happens if a non US manufacturer begins an abbreviated IDE study in the United States without a proper US sponsor of record?

Proceeding without a US sponsor of record creates a significant regulatory compliance risk. FDA can issue a clinical hold, require the study to be suspended, or take enforcement action. IRBs reviewing the protocol will typically ask for sponsor identification as part of the approval process, and a non US entity listed as its own sponsor will raise flags at that stage. Correcting the sponsor designation mid-study is possible but disruptive and requires notifying all participating IRBs and updating all study documentation. The better approach is to assess the sponsor structure before the study begins and prepare the designation correctly from the outset.

Ready to assess your IDE pathway and prepare a compliant US sponsor structure? Book a free discovery call with Andre Butler and the ADB Consulting and CRO Inc. regulatory team at adbccro.com. We work with medical device startups, VP Regulatory teams, and non US manufacturers at every stage of clinical planning to review their study designs and prepare the regulatory infrastructure their US investigations require.

Related reading: our US Sponsor of Record program covers this in more depth.